Over 62,000 individuals in England burdened with severe hand eczema may soon find relief thanks to a newly approved treatment available through the NHS. The National Institute for Health and Care Excellence (NICE) has endorsed the use of delgocitinib, marketed as Anzupgo by Leo Pharma, a decision that could potentially lead to significant savings for the NHS.
This topical cream is designed for adults experiencing moderate to severe chronic hand eczema, a condition that results in dry, sore, cracked, and itchy skin, complicating daily activities.
The condition poses particular challenges for those whose jobs demand frequent handwashing, such as healthcare professionals or outdoor workers. The delgocitinib cream is meant to be applied twice daily to the affected hands and wrists and can be used in the comfort of one’s home.
NICE advises that delgocitinib be offered to patients who have limited treatment options, especially when steroid creams are ineffective or unsuitable. Current alternatives for these patients include ultraviolet light therapy, which necessitates regular hospital visits, or retinoid medication, known for side effects such as dizziness, dry eyes, dry mouth, hair loss, anemia, and conjunctivitis.
NICE anticipates that the availability of delgocitinib could decrease the need for outpatient procedures like phototherapy and create more opportunities for other patients needing specialized care. The NHS is set to offer delgocitinib within 90 days.
